• Explore /
  • Poster
  • / Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03).

Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03).

Abstract Poster

Authors

null

Kazutaka Narui

Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan

Kazutaka Narui , Toshinari Yamashita , Masahiro Kitada , Hidetoshi Kawaguchi , Masaya Hattori , Tetsuhiro Yoshinami , Nobuki Matsunami , Kazuhiro Yanagihara , Teru Kawasoe , Takeshi Nagashima , Hiroko Bando , Hiroshi Yano , Yoshie Hasegawa , Rikiya Nakamura , Masahiro Kashiwaba , Norikazu Masuda , Satoshi Morita , Shinji Ohno , Masakazu Toi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

000012232

Citation

J Clin Oncol 35, 2017 (suppl; abstr 1025)

DOI

10.1200/JCO.2017.35.15_suppl.1025

Abstract #

1025

Poster Bd #

17

Abstract Disclosures

Similar Posters

First Author: Farrah Datko

First Author: Edith A. Perez

First Author: WanChen Hsieh

First Author: Nicholas Patrick McAndrew